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Abstract 
Purpose: To determine the correlation between miRNAs; miR-96, miR-422a and miR584, and colon 
cancer, and also to test whether any of these miRNAs can act as non-invasive biomarkers in colon 
cancer   
Methods: The tumor samples and the corresponding normal mucosa used in this study were collected 
from 60 patients diagnosed with colon cancer. HT-29, HCT-116 and SW-620 cell lines were used for 
miRNA expression profiling. Total RNA was extracted using kit-based methods with minor modifications, 
and specific miRNAs were detected and quantified by quantitative real-time polymerase chain reaction 
[RT-PCR].  
Results: The results indicate down-regulation of miR-96, miR-584 and miR-422a in colon cancer tissue 
and decreased expression levels in the three colon cancer cell lines (all p < 0.01). Lower miRNA 
expression levels are correlated with increased tumor size.  
Conclusion: This study shows that miR-96, miR-584 and miR-422a are down-regulated in colon cancer 
and are associated with tumor size. Thus, the ratio of miR-96/miR-638 in plasma is a potential non-
invasive biomarker in colon cancer. 
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MicroRNAs (miRNAs) are relatively newly 
discovered class of molecules that play crucial 
roles in cellular processes in humans and other 
mammals. miRNAs are transcribed by RNA 
polymerase II and do not code for any proteins, 
and are of varying lengths ranging between 20 
and 25 nucleotides [1]. Previously unknown, 
miRNAs have been shown to play significant 
roles in cancer related pathways such as 
invasion, migration, proliferation, apoptosis and 
other aspects of tumorigenesis [2,3]. The precise 
mechanisms of miRNA function in mammals are 
still debatable. However, several years of literary 
evidence suggest that miRNAs regulate gene 
expression through precise sequence specific 
base pairing at the 3’ UTR of the target mRNA or 
at the translational level [4]. 
  
Colon cancer is the cancer of the colon with a 
million new cases reported each year globally [5]. 
In the United States alone, colon cancer is the 
third most prevalent form of cancer with 95,000 
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cases reported each year, and second most 
leading cause of cancer related deaths. Similar 
to other types of cancer, survival rates of colon 
cancer patients depend on the early detection of 
colon cancer. Therefore, it is important to detect 
colon cancer at an early stage. However, only 40 
% of colon cancers are detected at an early 
stage. Several studies have shown that early 
detection of colon cancer is highly curable. The 
present methods of treatment include 
independent or a combination of surgical 
procedures, chemotherapy, radiotherapy and 
other targeted therapies depending on the stage 
of cancer. Since the afore-stated procedures are 
based on the late onset of colon cancer, it is 
important to develop early stage detection 
methods that have the potential to complement 
the aforementioned standard procedures to cure 
colon cancer or improve the life span of an 
individual.  
 
Given the crucial association between miRNAs 
and cancer, several studies have classified 
different types of human cancers based on 
miRNA expression profiles [6,7]. Aberrant 
expression of miRNAs has been associated with 
almost every type of cancer. Expression analysis 
by RT-PCR revealed miR-221, miR-376a and 
miR-301 to be differentially expressed in 
pancreatic cancer providing new insights into 
pancreatic tumorigenesis [8]. A recent study has 
shown the let-7 miRNA cluster, miR-214, miR-
199a*, miR-200a and miR-100 to be frequently 
deregulated in ovarian cancer [9]. Similarly, 
miRNA expression profiling of prostate and 
breast cancer cells have revealed a total of 51 
miRNAs that were either upregulated or 
downregulated in prostate cancer and a total of 
133 miRNAs in breast tumors [10,11]. 
 
Expression profiling of miRNAs have been 
carried out in the last decade in colon cancer cell 
lines or tissues and these studies have 
established that aberrant expression of miRNAs 
is associated with colon or colorectal cancer. 
One of the studies analyzed the expression of 
156 miRNAs in colorectal cancer and found a 
group of 13 miRNAs with aberrant expression 
profiles of which miR-31, miR-96, miR-133b, 
miR-135b, miR-145, and miR-183 were most 
significantly deregulated [12]. In another study, a 
total of 95 plasma miRNAs have been analyzed 
in colorectal cancer patients and 5 miRNAs have 
been found to be upregulated compared to their 
corresponding controls [13].  
 
Similarly, in this study, we carried out expression 
profiling of miR-96, miR-422a and miR-584 in 
colon cancer and show that all the three miRNAs 
are downregulated. Lower expression levels of 
these miRNAs have been correlated with 
increased tumor size. Also, we demonstrate that 
circulating level of miR-96 in plasma has the 
potential as a non-invasive biological marker for 




Patient characteristics and tissue samples 
 
The tumor samples and the corresponding 
normal mucosa used in this study were collected 
from 60 patients diagnosed with CRC. After 
collection, all the samples were immediately flash 
frozen and stored at – 80 °C.  The patients were 
being treated at The Second Affiliated Hospital of 
Wenzhou Medical University. The Medical Ethics 
Committee of The Second Affiliated Hospital of 
Wenzhou Medical University granted approval for 
this study. The samples were collected only after 
a written consent was obtained from the patients 
or their guardians. The histological grade of 
cancer was classified using the TNM staging 
system as per World Health Organization 
standards [20].  
 
Cell lines and culture 
 
HT-29, HCT-116 and SW-620 cell lines were 
obtained from The Second Affiliated Hospital of 
Wenzhou Medical University. HT-29 and HCT-
116 cell lines were cultured in McCoy’s 5a media 
(Invitrogen, USA) supplemented with 10 % Fetal 
Bovine Serum (FBS). SW-620 cell line was 
cultured in L15 media (Sigma Aldrich, USA) 
supplemented with 2 mM glutamine and 10 % 
FBS. All the cell lines were cultured at 37 °C in a 
humidified atmosphere of 5 % CO2. 
 
RNA extraction and purification 
 
RNA was extracted from the normal mucosa and 
the cancerous tissue samples according to the 
following procedure. Briefly, the flash frozen 
tissue samples were homogenized in presence 
of 0.5 ml of TRIZOL/50 mg of tissue. In the next 
phase separation step, 0.1 ml of chloroform was 
added to the aforementioned suspension 
solution. Following the phase separation step, 
RNA was precipitated by addition of 0.25 ml of 
isopropanol. Following centrifugation at 12000 g, 
the RNA pellet was washed with 80 % ethanol, 
centrifuged at 8000 g/10 min, air-dried and re-
dissolved in 50 μL of DPEC treated water. The 
contaminating DNA was removed by DNAse 
treatment kit according to the manufacturer’s 
instructions (Ambion, USA).  For the purification 
of RNA, RNeasy column purification kit was used 
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(Qiagen, USA) according to the manufacturer’s 
instructions. The total RNA was eluted in 50 μL 
of DPEC treated water and quantified on a 
NanoDrop 1000 (Thermo Scientific, USA).   
 
Quantitative real-time polymerase chain 
reaction [RT-PCR] 
 
The expression profiling of colon tissue miRNA 
was performed by Taqman assays. The miRNAs, 
miR-96, miR-584 and miR-422a, endogenous 5s 
rRNA primers and probes were purchased from 
Invitrogen, USA. The sequences of specific 
primers used in this study are indicated in Table 
1. The final volume of the PCR mixture was 50 
μL and it contained 0.3 μM probe, 0.3 μM of 
forward and reverse primers, 1X PCR buffer, 0.4 
mM dNTPs and Taq DNA polymerase. The 
thermocycling conditions included initial 
denaturation at 95 ◦C for 5 min, followed by 35 
cycles of 95 ◦C for 20 s, 58 ◦C for 30 s, and 68 
◦C for 40 s. Corresponding negative control 
without a template was used in all the runs and 
all the PCR runs were carried out in triplicates. 
miRNA expression levels were quantified using 
the ABI Prism 7000 Sequence detection system 
(Applied Biosystems, USA). The relative 
expression levels of the miRNAs were calculated 
using the 2-ΔΔCT method. 5s rRNA was used as 
an internal control to normalize the data. 
 
Table 1: Sequences of specific primers used in this 
study 
 
miR-96 Forward: 5’ CGGAGCACCTTACCCACTT 3’ 




Forward: 5’ CAGGGTTGCTGTTACTGGAG 
3’ 











The differential expression of miRNA between 
colon cancer samples and the corresponding 
normal mucosa was assessed by a two-sided 
Student’s t-test. The relationship between miR-
96, miR-584 and miR-422a expression levels 
and clinicopathological characteristics were 
analyzed by non-parametric tests.  
 
A p-value of < 0.05 was considered statistically 
significant. All statistical analyses were 
performed using GraphPad Prism 5 software and 




Expression levels of miR-96, miR-584 and 
miR-422a in colon cancer tissues  
 
The expression levels of miR-96, miR-584 and 
miR-422a were analyzed in 60 colon cancer 
patient tissue samples and their adjacent normal 
mucosal counterparts using quantitative RT-
PCR. Clinical characteristics of the 60 patients 
involved in this study are summarized in Table 2. 
Quantification analysis indicated that the levels of 
miR-96, miR-584 and miR-422a were 
significantly downregulated in most of the colon 
cancer tissue samples (Fig 1a, b and c). Next, 
we went ahead to analyze the differential 
expression levels of all the three miRNAs with 
respect to the adjacent normal mucosal tissues. 
Differential expression analysis using ΔCt 
method revealed that the expression levels for 
miR-96 decreased by a factor of 40-fold in 50 out 
of 60 cancer tissue samples relative to the 
normal mucosal tissue counterparts (Fig 2a, p < 
0.01). Similarly, the expression levels of miR-584 
and miR-422a were decreased by a factor of 70-
fold in 55 out of 60 cancer tissue samples, and 
by a factor of 60-fold in 45 out of 60 cancer 
tissue samples (Fig 2b and c, p <0.01). 
 
Expression of miR-96, miR-584 and miR-422a 
in colon cancer cell lines  
 
We evaluated the expression levels of miR-96, 
miR-584 and miR-422a in the colon cancer cell 
lines HCT-116, SW-620 and HT-29. The results 
indicated significantly lower expression levels of 
miR-96, miR-584 and miR-422a in all the three 
colon cancer cell lines compared to the 
randomized normal mucosal tissue from patients 
(Fig 2d). 
 
Association between miRNA expression and 
clinicopathological characteristics of colon 
cancer patients 
 
We evaluated the association between miR-96, 
miR-584 and miR-422a expression levels and 
clinicopathological characteristics in colon cancer 
patients. No significant correlation could be 
obtained between low expression levels of miR-
96, miR-584 and miR-422a and characteristics 
such as patients’ gender, age, the tumor and the 
clinical stages, lymph node metastasis and 
invasion. However, our correlation analysis 
suggested a significant correlation between lower 
expression levels of miR-96, miR-584 and miR-
422a and the size of the tumor, irrespective of 
other clinicopathological characteristics. Our 
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results suggest that, lower expression levels of 
the aforementioned miRNAs are associated with 
increased tumor size (Table 2, all p < 0.05). 
 
Ratio of miR-96/miR-638 is a potential 
biomarker for colon cancer  
 
We next wanted to investigate whether the 
expression levels of miR-96, miR-584 or miR-
422a in blood could act as a non-invasive viable 
biological marker to discriminate colon cancer 
patients from healthy individuals. We measured 
the expression levels of miR-96, miR-584 and 
miR-422a independently in plasma samples from 
25 colon cancer patients with respect to the 
healthy individual samples by quantitative RT-
PCR. Recent studies have shown that, since the 
levels of plasma miR-638 are quite stable, miR-
638 can be used as a standard to improve the 
precision of the analysis [14]. Therefore, we 
analyzed the ratios of miR-96, miR-584 and 
miR422a levels to miR-638 levels in the plasma 
samples from healthy and colon cancer patients. 
The ratio of plasma levels of miR-584/miR-638 
and miR-422a/miR638 from colon cancer 
patients could not be unambiguously 
distinguished from the aforementioned ratios 
from healthy individuals (Figure 3 a and b). 
However, the analysis revealed an increased 
ratio of miR- 96/miR-638 in the plasma samples 
from the colon cancer patients with respect to the 
healthy individuals (Figure 3c). Thus, the levels 
of miR-96/miR-638 can act as a potential 
biomarker in the prognosis of colon cancer. 
 
 
Table 2: Association between miR-96, miR-584 and miR-422a expression levels and clinicopathological 
characteristics in colon cancer patients 
 
Patient 
characteristics N miR-96 miR-584 miR-422a 
Gender         
 Male 35 0.264 0.179 0.243 
 Female 25 0.149 0.215 0.243 
 P-value   0.318 0.209 0.196 
Age (years)      > 70 37 0.125 0.116 0.232 
 < 70 23 0.187 0.288 0.148 
 P-value   0.576 0.132 0.212 
Histological grade      Well defined 43 0.115 0.252 0.174 
 Poorly defined 17 0.198 0.165 0.279 
 P-value   0.15 0.798 0.5 
pTNM stage      I+II 42 0. 179 0.219 0.137 
 III 18 0.129 0.176 0.185 
 P-value   0.379 0. 252 0.58 
pN stage      N0 33 0.156 0.129 0.165 
 N1 19 0.172 0.184 0.149 
 N2 8 0.155 0.169 0.183 
 P-value  0.698 0.539 0.236 Lymphatic vessel 
invasion         
 Positive 49 0.126 0.167 0.136 
 Negative 11 0.18 0.148 0.194 
 P-value  0.29 0.376 0.295 Tumor size (cm)         
 < 5 26 0.272 0.317 0.184 
 > 5 34 0.269 0.242 0.211 
P-value   0.025 0.034 0.03 
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Figure 1: Expression levels of (a) miR-96, (b) miR-584 and (c) miR-422a in 60 colon cancer patient tissues. 
Quantification analysis indicated that the levels of miR-96, miR-584 and miR-422a were significantly 




The last decade has witnessed advancement in 
colon cancer research and diagnosis, however it 
is still one of the deadliest form of cancer with a 
number of fatalities per year. Since the survival 
rates of colon cancer patients depend on the 
early detection of cancer it has become 
necessary to identify biological markers for a 
better diagnosis. In the last decade, different 
classes of molecules have been identified as 
potential biomarkers for colon cancer and one 
such intriguing class of molecules is the miRNAs 
[15]. Large-scale miRnome studies have been 
carried out in different human solid tumors of 
breast, colon, pancreas, lung and stomach and 
identified a large cohort of miRNAs that have 
been over-expressed or under-expressed 
[16,17]. Several other studies identified such 
“miRNA signatures” in cancer and conclusively 
establish that miRNAs play a critical role in 
cancer pathogenesis, playing role of either 
oncogenes or tumor suppressor genes. 
 
Several published literature has provided 
sufficient evidence that miR-96, miR-584 and 
miR-422a are often de-regulated in cancer 
causing pathways. While these miRNAs have 
been associated with colon cancer and reported 
previously [18], to the best of our knowledge, a 
comprehensive validation and characterization of 
these miRNAs in colon cancer patient tissue 
samples and cell lines, and the ability of these 
miRNAs to act as a viable biomarker in the 
prognosis of colon cancer is still required.  
 
Firstly, the levels of miR-96, miR-584 and miR-
422a were assessed in colon cancer tissue and 
adjacent normal mucosal tissue counterparts 
using real-time PCR owing to its rapid 
quantification as well as sensitivity. Significantly 
lower expression levels of these miRNAs in the 
cancer tissue compared with the healthy tissue 
indicated that miR-96, miR-584 and miR-422a 
are down-regulated in colon cancer. Next, the 
levels of these miRNAs were assessed in some 
routinely used colon cancer cell lines.  
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Figure 2: Differential expression analysis of all (a) miR-96, (b) miR-584 and (c) miR-422a in colon cancer tissues 
(CCT) with respect to the adjacent normal mucosal tissues (NAT). Differential expression analysis was carried 
out by ΔCt method. Expression levels of miR-96, miR-584 and miR-422a were decreased by a factor of 40-fold, 
70-fold and 60-fold respectively (d) Expression levels of miR-96, miR-584 and miR-422a in HCT-116, SW-620 
and HT-29 colon cancer cell lines. miRNA expression analysis in colon cancer cell lines is relative to three 




Figure 3: Comparison of miR-584, miR-422a and miR-96 levels in the plasmas from normal individuals and colon 
cancer patients. The ratio between (a) miR-584, (b) miR-422a and (c) miR-96 to miR-638 were quantitated by 
RT-PCR. Bars, s.d. As it is evident from the figure, the miR-96/miR-638 ratio from the colon cancer plasma 
samples could be unambiguously distinguished from the normal plasma samples 
 
Similar to the patient tissue samples, HCT-116, 
SW-620 and HT-29 colon cancer cell lines 
showed subdued expression levels of these 
miRNAs. Further, the correlation between low 
miRNA expression levels and clinicopathological 
characteristics of colon cancer patients was 
evaluated. This study indicated an interesting 
correlation between low expression levels of 
miR-96, miR-584 and miR-422a with increase in 
size of the tumor in colon cancer patients.  
 
A similar study has been carried out in the past in 
29 colorectal cancer tissues and the study shows 
the expression of miR-21, -31, -143 and -145 to 
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be altered in CRC and is related to 
clinicopathological characteristics such as tumor 
size and lymph node metastasis [19]. Thus, it is 
evident that miR-96, miR-584 and miR-422a 
show altered expression levels in colon cancer 
and it is likely that these miRNAs have the 
potential as a biomarker in the prognosis of colon 
cancer. 
 
miRNAs have been shown to have a promising 
potential as prognostic biomarkers for various 
types of cancer. Therefore, we investigated the 
predictive value of miR-96, miR-584 and miR-
422a in blood plasma as a viable prognostic 
biomarker for colon cancer. Quantification of the 
ratios of miR-584/miR-638 levels and miR-
422a/miR638 levels did not yield success, as a 
clear distinction could not be obtained with 
respect to healthy individuals. However, we 
found the ratio of miR-96 to miR-638 to be 
increased in the plasma samples of colon cancer 
patients compared to healthy individuals. The 
distinction was remarkable and thus the levels of 
miR-96/miR-638 have the potential as a viable 
non-invasive biomarker for colon cancer.  Similar 
quantification studies were carried out in the 
plasma samples of hepatocellular carcinoma 




This study shows that miR-96, miR-584 and miR-
422a are downregulated in colon cancer and are 
associated with tumor size. The levels of miR-
96/miR-638 has the potential of a non-invasive 
biomarker in colon cancer. Translating this 
finding into clinical practice would require a 
thorough and systematic development of 
diagnostics followed by randomized 
investigations and validations for demonstrating 
the efficacy of such non-invasive biomarkers in 
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